Vesnarinone (Synonyms: 维司力农; OPC-8212)
目录号: PL09692 纯度: ≥98%
CAS No. :81840-15-5
商品编号 规格 价格 会员价 是否有货 数量
PL09692-5mg 5mg ¥2432.50 请登录
PL09692-10mg 10mg ¥4252.50 请登录
PL09692-25mg 25mg ¥9327.50 请登录
PL09692-50mg 50mg ¥14465.00 请登录
PL09692-100mg 100mg ¥22501.00 请登录
PL09692-200mg 200mg 询价 询价
PL09692-500mg 500mg 询价 询价
PL09692-10mM*1mLinDMSO 10mM*1mLinDMSO ¥2796.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Vesnarinone
中文别名
维司力农;3,4-二氢-6-[4-(3,4-二甲氧苯甲酰)-1-哌嗪基]-2(1H)-喹啉酮;威那利酮
英文名称
Vesnarinone
英文别名
Vesnarinone;1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-Piperazine;Arkin;Pieranometazine;6-(4-(3,4-dimethoxybenzoyl)piperazin-1-yl)-3,4-dihydroquinolin-2(1H)-one;6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one;3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline;6-[4-(3,4-dimethoxy-benzoyl)-1-piperazinyl]-3,4-dihydrocarbostyril;Arkin-Z;DRG-0210;OPC8212;OPC-8212;Piteranometozine;Vesnarinona [Spanish];Vesnarinonum [Latin];6-[4-(3,4-Dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydro-2(1H)-quinolinone;OPC 8212
Cas No.
81840-15-5
分子式
C22H25N3O4
分子量
395.45
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Vesnarinone (OPC-8212) 是一种具有口服活性的 phosphodiesterase 3 (PDE3) 抑制剂。Vesnarinone 可增加钙通量,减少钾通量。Vesnarinone 具有剂量依赖性的正性肌力活性,可用于心力衰竭的研究。
生物活性
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.
性状
Solid
体外研究(In Vitro)
Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner.
Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis.
Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay
体内研究(In Vivo)
Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Lewis rats (200 g)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. A Matsumori, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994 Mar;89(3):955-8.
[2]. E Cavusoglu, et al. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail. 1995 Jun;1(3):249-57.
溶解度数据
In Vitro: DMSO : 16.67 mg/mL (42.15 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2